Risk factors
Aclaris Therapeutics (ACRS) risk factors
Item 1A of every Aclaris Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors71 risks13 new5 dropped14 reworded
Aclaris added artificial intelligence competition and macroeconomic pressures like tariffs as new key business risks.
Filed Feb 26, 2026 - FY2024 10-K risk factors63 risks
Aclaris Therapeutics relies heavily on external partners to develop and commercialize its preclinical and clinical-stage drug candidates. The company faces a substantial accumulated deficit of $902.9 million and requires significant additional capital. Patent protection and complex regulatory pathways heavily dictate the viability of its kinase inhibitor and biologic pipeline.
Filed Feb 27, 2025